CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues	[1]	$ 12,680	$ 13,298	$ 39,062	$ 39,670
Costs and expenses:
Cost of sales	[1],[2]	2,602	2,694	7,611	8,173
Selling, informational and administrative expenses	[1],[2]	3,260	3,494	10,110	10,448
Research and development expenses	[1],[2]	2,283	2,008	5,827	5,549
Amortization of intangible assets	[1]	1,212	1,253	3,578	3,640
Restructuring charges and certain acquisition-related costs	[1]	365	85	295	172
(Gain) on completion of Consumer Healthcare JV transaction	[1]	(8,087)	0	(8,087)	0
Other (income)/deductions––net	[1]	319	(414)	537	(1,143)
Income from continuing operations before provision for taxes on income	[1],[3]	10,727	4,177	19,190	12,831
Provision for taxes on income	[1]	3,047	66	2,566	1,270
Income from continuing operations	[1]	7,680	4,111	16,625	11,562
Discontinued operations––net of tax	[1]	4	11	4	10
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	7,684	4,122	16,628	11,571
Less: Net income attributable to noncontrolling interests	[1]	4	8	19	25
Net income attributable to Pfizer Inc.	[1]	$ 7,680	$ 4,114	$ 16,609	$ 11,546
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 1.38	$ 0.70	$ 2.98	$ 1.96
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	1.38	0.70	2.98	1.96
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	1.36	0.69	2.92	1.92
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 1.36	$ 0.69	$ 2.92	$ 1.92
Weighted-average shares––basic	[1]	5,545	5,875	5,581	5,899
Weighted-average shares––diluted	[1]	5,649	5,986	5,690	5,998

[1] Amounts may not add due to rounding.

[2] Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

[3] Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $43 million in the third quarter of 2019 and $91 million in the third quarter of 2018, and $184 million in the first nine months of 2019 and $226 million in the first nine months of 2018 from our investment in ViiV. For additional information, see Note 4.

[4] Amounts may not add due to rounding.

[5] Amounts may not add due to rounding.

[6] Amounts may not add due to rounding.